News
Three years after Daiichi Sankyo's FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the US ...
Vendors and Providers | News, analysis, features, how-tos, and videos ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback